Skip to main content
Premium Trial:

Request an Annual Quote

FTC: MDS Must Sell Arcturus Business to Life Technologies to Proceed with Danaher Deal

NEW YORK (GenomeWeb News) – The US Federal Trade Commission today said that it has ordered MDS to sell its Arcturus laser microdissection business to Life Technologies as a condition of approving its deal to sell its MDS Analytical Technologies unit to Danaher.

The FTC said that the sale would "resolve FTC charges that Danaher's acquisition of MDS Analytical Technologies would harm competition in the North American market for laser microdissection devices." It noted that Danaher and MDS are two of only four North American suppliers of such devices.

The acquisition would have combined Danaher's Leica brand of devices with MDS's Arcturus brand, which the FTC said would have led to increased prices and decreased innovation for this type of equipment. In addition, it contended that entry by a new firm into the field would be unlikely to offset the anticompetitive effects of the proposed acquisition.

The sale of the business to Life Technologies will clear the path for Danaher to complete its $1.1 billion acquisition of MDS Analytical Technologies, as well as the mass spectrometry joint venture of MDS and Life Technologies. MDS is to receive $650 million of that $1.1 billion, with Life Technologies getting the rest.

The FTC said that under the proposed order, Danaher and MDS must sell to Life Technologies all of the products and equipment that Life Technologies needs to run the laser microdissection business. In addition, all key Arcturus employees must be made available to Life Technologies, as well as any other employees who may be needed to ensure the divestiture is a success. MDS must also "provide Life Technologies with all of the intellectual property and patent licenses necessary to compete immediately in the North American laser microdissection market."

The FTC will accept comments on the proposed order until March 1, after which it will decide whether to make the order final.

In a statement issued this afternoon, MDS called the provisional anti-trust approval "significant milestone" toward closing the deal with Danaher. The firms expect to complete the transaction by the end of the first quarter of 2010.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.